Rhythm Biosciences Ltd (ASX:RHY) Records First Commercial Sales of geneType Products
Operational Achievements
Rhythm Biosciences Ltd has recorded its first commercial sales under its leadership since restoring Genetype’s commercial capabilities in February. The initial sales in 2025 were patient cases assumed during the Genetype acquisition, and Rhythm has now generated new sales.
Future Outlook
Commercial B2B sales of geneType™ products are expected to grow throughout the year, supported by a reinvigorated team and processes. Strategic growth will focus on enterprise market segments and geographic expansion.
Executive Comments
Dr David Atkins, CEO & Managing Director, stated, “It is most pleasing to have crossed this threshold, with Rhythm from here on being able to record commercial sales revenues. Although non-material, at present, we are confident that the suite of products will support commercial revenue growth over ensuing periods. It is a credit to the dedication of the Rhythm and ongoing Genetype team to have re-established commercial activities so soon. With growing revenues expected from the geneType™ product portfolio, we look forward to adding to this with ColoSTAT® commercial revenues in the next financial year.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
